Sangamo Therapeutics, Inc.
SGMO
$0.5863
$0.01312.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5,042.13% | 1,238.25% | 269.78% | 425.77% | -94.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5,042.13% | 1,238.25% | 269.78% | 425.77% | -94.79% |
| Cost of Revenue | 11.81% | -30.89% | -53.49% | -51.42% | -59.11% |
| Gross Profit | 63.22% | 48.12% | 67.00% | 145.46% | 54.46% |
| SG&A Expenses | -24.63% | -14.52% | -26.01% | -37.86% | -18.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.29% | -26.84% | -47.83% | -48.76% | -51.03% |
| Operating Income | 50.28% | 39.74% | 58.28% | 121.15% | 46.58% |
| Income Before Tax | 44.64% | 37.79% | 60.67% | 110.46% | 70.15% |
| Income Tax Expenses | -63.51% | 21.43% | -56.99% | -93.07% | 101.18% |
| Earnings from Continuing Operations | 44.68% | 37.67% | 61.20% | 110.25% | 68.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.68% | 37.67% | 61.20% | 110.25% | 68.45% |
| EBIT | 50.28% | 39.74% | 58.28% | 121.15% | 46.58% |
| EBITDA | 51.36% | 40.12% | 59.08% | 125.39% | 44.94% |
| EPS Basic | 56.07% | 48.97% | 67.22% | 107.65% | 73.04% |
| Normalized Basic EPS | 54.63% | 46.28% | 66.07% | 119.28% | 53.72% |
| EPS Diluted | 56.07% | 48.97% | 65.86% | 106.78% | 73.04% |
| Normalized Diluted EPS | 54.63% | 46.28% | 66.07% | 118.74% | 53.72% |
| Average Basic Shares Outstanding | 25.99% | 22.14% | 18.33% | 17.60% | 16.99% |
| Average Diluted Shares Outstanding | 25.99% | 22.14% | 18.33% | 20.97% | 16.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |